Drugmaker Valeant cuts 2016 outlook, says it faces default risk
(Reuters) - Valeant Pharmaceuticals International Inc on Tuesday cut its 2016 revenue forecast by about 12 percent and said a delay in filing its annual report could mean a debt default, causing its shares to plunge.
No comments:
Post a Comment